NBIX Neurocrine Biosciences Inc

Price (delayed)

$107.69

Market cap

$10.06B

P/E Ratio

106.62

Dividend/share

N/A

EPS

$1.01

Enterprise value

$10.14B

Sector: Healthcare
Industry: Biotechnology

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights

The gross profit has soared by 54% YoY and by 3.6% from the previous quarter
Neurocrine Biosciences's revenue has surged by 54% YoY and by 3.6% QoQ
The company's equity rose by 40% YoY but it fell by 3.2% QoQ
Neurocrine Biosciences's quick ratio has plunged by 73% YoY and by 6% from the previous quarter
NBIX's EPS has dropped by 55% since the previous quarter

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
93.43M
Market cap
$10.06B
Enterprise value
$10.14B
Valuations
Price to earnings (P/E)
106.62
Price to book (P/B)
12.49
Price to sales (P/S)
9.64
EV/EBIT
74.15
EV/EBITDA
69.81
EV/Sales
9.73
Earnings
Revenue
$1.04B
EBIT
$136.77M
EBITDA
$145.26M
Free cash flow
$232.94M
Per share
EPS
$1.01
Free cash flow per share
$2.5
Book value per share
$8.62
Revenue per share
$11.17
TBVPS
$16.11
Balance sheet
Total assets
$1.5B
Total liabilities
$698.3M
Debt
$508M
Equity
$804.3M
Working capital
$545.9M
Liquidity
Debt to equity
0.63
Current ratio
1.89
Quick ratio
1.81
Net debt/EBITDA
0.55
Margins
EBITDA margin
13.9%
Gross margin
99.1%
Net margin
9%
Operating margin
13.4%
Efficiency
Return on assets
6.6%
Return on equity
12.6%
Return on invested capital
11.8%
Return on capital employed
15.3%
Return on sales
13.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
-1.46%
1 week
-3.91%
1 month
12.98%
1 year
0.31%
YTD
12.35%
QTD
12.35%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.04B
Gross profit
$1.03B
Operating income
$139.92M
Net income
$93.4M
Gross margin
99.1%
Net margin
9%
The net margin has soared by 190% YoY but it has shrunk by 56% QoQ
The operating margin has soared by 100% YoY but it has plunged by 51% from the previous quarter
The company's net income has shrunk by 54% QoQ
The gross profit has soared by 54% YoY and by 3.6% from the previous quarter

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
P/E
106.62
P/B
12.49
P/S
9.64
EV/EBIT
74.15
EV/EBITDA
69.81
EV/Sales
9.73
NBIX's EPS has dropped by 55% since the previous quarter
The price to earnings (P/E) is 8% lower than the last 4 quarters average of 116.0
The company's equity rose by 40% YoY but it fell by 3.2% QoQ
NBIX's price to book (P/B) is 17% lower than its 5-year quarterly average of 15.1 and 3.2% lower than its last 4 quarters average of 12.9
The stock's price to sales (P/S) is 91% less than its 5-year quarterly average of 108.5 and 7% less than its last 4 quarters average of 10.4
Neurocrine Biosciences's revenue has surged by 54% YoY and by 3.6% QoQ

Efficiency

How efficient is Neurocrine Biosciences business performance
The ROE has soared by 193% YoY but it has plunged by 58% from the previous quarter
The company's return on invested capital has surged by 157% YoY but it fell by 41% QoQ
Neurocrine Biosciences's return on assets has shrunk by 57% QoQ
NBIX's return on sales has surged by 52% year-on-year but it is down by 48% since the previous quarter

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
NBIX's total assets is 115% more than its total liabilities
Neurocrine Biosciences's quick ratio has plunged by 73% YoY and by 6% from the previous quarter
The company's current ratio has shrunk by 73% YoY and by 6% QoQ
The debt is 37% lower than the equity
The company's equity rose by 40% YoY but it fell by 3.2% QoQ
NBIX's debt to equity is down by 24% year-on-year but it is up by 3.3% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.